(Q34805650)

English

Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS S

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 August 2017

Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS S (English)

1 reference

Europe PubMed Central

4 August 2017

hypercholesterolemia

0 references

circulatory system

1 reference

based on heuristic

inferred from title

Helen M. Colhoun

object named as

Helen M Colhoun

2

0 references

author name string

Jennifer G Robinson

1

1 reference

Europe PubMed Central

4 August 2017

Harold E Bays

3

1 reference

Europe PubMed Central

4 August 2017

Peter H Jones

4

1 reference

Europe PubMed Central

4 August 2017

Yunling Du

5

1 reference

Europe PubMed Central

4 August 2017

Corinne Hanotin

6

1 reference

Europe PubMed Central

4 August 2017

Stephen Donahue

7

1 reference

Europe PubMed Central

4 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

30 September 2014

1 reference

Europe PubMed Central

4 August 2017

Clinical Cardiology

1 reference

Europe PubMed Central

4 August 2017

37

1 reference

Europe PubMed Central

4 August 2017

10

1 reference

Europe PubMed Central

4 August 2017

597-604

1 reference

Europe PubMed Central

4 August 2017

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282386

8 July 2018

An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282386

8 July 2018

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282386

8 July 2018

Statins for the primary prevention of cardiovascular disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282386

8 July 2018

2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282386

8 July 2018

Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282386

8 July 2018

Heart Disease and Stroke Statistics--2013 Update: A Report From the American Heart Association

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282386

8 July 2018

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282386

8 July 2018

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282386

8 July 2018

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282386

8 July 2018

Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282386

8 July 2018

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282386

8 July 2018

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282386

8 July 2018

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282386

8 July 2018

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282386

8 July 2018

Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282386

8 July 2018

Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries

1 reference

https://api.crossref.org/works/10.1002%2FCLC.22327

21 January 2018

Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey.

1 reference

https://api.crossref.org/works/10.1002%2FCLC.22327

21 January 2018

Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1002%2FCLC.22327

21 January 2018

Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.

1 reference

https://api.crossref.org/works/10.1002%2FCLC.22327

21 January 2018

Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals.

1 reference

https://api.crossref.org/works/10.1002%2FCLC.22327

21 January 2018

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con

1 reference

https://api.crossref.org/works/10.1002%2FCLC.22327

21 January 2018

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy

1 reference

https://api.crossref.org/works/10.1002%2FCLC.22327

21 January 2018

MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets

1 reference

https://api.crossref.org/works/10.1002%2FCLC.22327

21 January 2018

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

1 reference

https://api.crossref.org/works/10.1002%2FCLC.22327

21 January 2018

Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease

1 reference

https://api.crossref.org/works/10.1002%2FCLC.22327

21 January 2018

Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1002%2FCLC.22327

7 January 2021

based on heuristic

inferred from DOI database lookup

Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein lowering

1 reference

https://api.crossref.org/works/10.1002%2FCLC.22327

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CLC.22327

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34805650&oldid=1978417281"